Global mRNA Vaccines and Therapeutics Market - 1-3 USERS:2021

Market Report Coverage :
Start Year : by COVID-19 vaccinesStart Year: 2021by non-COVID-19 vaccinesStart Year: 2026 - Forecast Year : by COVID-19 vaccinesForecast Year: 2025by non-COVID-19 vaccinesForecast Year: 2031 - Start Value : by COVID-19 vaccines51,656.8 Million in 2021by non-COVID-19 vaccines59.3 Million in 2026 - Forecast Value : by COVID-19 vaccines28,926.0 Million by 2025by non-COVID-19 vaccines1,691.6 Million by 2031 - CAGR % : 0%
Description :
Market Report Coverage - mRNA Vaccines and TherapeuticsMarket Segmentation• Application – COVID-19 mRNA Vaccines and Non-COVID-19 mRNA Vaccines• mRNA Type – Nucleoside-Modified mRNA, Unmodified mRNA, and Self-Amplifying mRNARegional Segmentation• North America – U.S., and Canada• Europe – Germany, France, U.K., Italy, Spain, and Rest-of-Europe• Asia-Pacific – China, Japan, South Korea, Australia, and Rest-of-Asia-Pacific• Latin America – Brazil, Mexico, and Rest-of-Latin America• Rest-of-the-WorldGrowth Drivers• Growing Cases of COVID-19 Globally• Favorable Regulatory Environment• Significant External Funding for the Development of mRNA-Based COVID-19 VaccinesMarket Challenges• Logistical Challenges Associated with mRNA-Based COVID-19 Vaccines• High Price Associated with mRNA-Based COVID-19 VaccinesMarket Opportunities• Growing Emphasis on Research and Development for Non-COVID-19 ApplicationsKey Companies ProfiledArcturus Therapeutics Holdings Inc., BioNTech SE, CureVac N.V., Daiichi Sankyo Company, Limited., ethris GmbH, GlaxoSmithKline plc, Gennova Biopharmaceuticals Ltd, Moderna, Inc., Pantherna Therapeutics GmbH, Providence Therapeutics, Silence Therapeutics, Translate Bio, VERSAMEB AG, and Verve Therapeutics, Inc.Key Questions Answered in this Report:• What are the major market drivers, challenges, and opportunities in the global mRNA vaccines and therapeutics market?• What are the key development strategies being implemented by the major players in order to sustain in the competitive market? • What are the key regulatory implications in developed and developing regions for the global mRNA vaccines and therapeutics market?• How is each segment of the market expected to grow during the forecast period, 2021-2031?• Who are the leading players with significant offerings to the global mRNA vaccines and therapeutics market, and what is the expected market dominance for each of these leading players?• What are the adoption trends for mRNA vaccines and therapeutics in established economies and emerging economies across the world? • Which companies are anticipated to be highly disruptive in the future, and why?• What are the current clinical unmet needs that are being faced in the global mRNA vaccines and therapeutics market?• What are the dynamics of various application areas and countries, which are impacting the global mRNA vaccines and therapeutics market?• What are the new market opportunities that are influencing the growth of the global mRNA vaccines and therapeutics market?• How is each segment of the market expected to grow during the forecast period from 2021 to 2031? Following are the segment types: • Application • mRNA Type • Region• What are the unmet needs currently existing in the global mRNA vaccines and therapeutics market?Market OverviewBIS healthcare experts have found the mRNA vaccines and therapeutics market to be one of the most rapidly evolving and dynamic markets, and the global market for mRNA vaccines and therapeutics for COVID-19 vaccines is predicted to decline at a CAGR of 13.50% over the forecast period of 2021-2025. Moreover, the global market for mRNA vaccines and therapeutics for non-COVID-19 vaccines is predicted to grow at a CAGR of 95.49% over the forecast period of 2026-2031. The overall global mRNA vaccines and therapeutics market is driven by certain factors, which include growing cases of COVID-19 globally, a favorable regulatory environment, and significant external funding for the development of mRNA-based COVID-19 vaccines.The market for COVID-19 is favored by the developments in the field of mRNA-based COVID-19 vaccines due to the growing cases of COVID-19 globally, favourable regulatory environment, and significant external funding for the development of mRNA-based COVID-19 vaccines. Additionally, the emergence of the new SARS-CoV-2 virus in different countries, coupled with the efficacy of mRNA vaccines against new strains, are some of the critical factors which are expected to bolster the market growth, particularly during, Q4 2020- Q4 2022. Furthermore, pharmaceutical companies are focusing on the development of new mRNA-based vaccine candidates for COVID-19 to support the healthcare authorities and the government to establish robust vaccination strategies. However, due to the expected transition of the ongoing COVID-19 pandemic into an endemic by the end of 2023, the market is anticipated to drastically decline by the end of 2025.The market for mRNA vaccines and therapeutics for non-COVID-19 is favored by the clinical developments which have been taking place to develop novel mRNA-based vaccines and therapies for non-COVID-19 applications, particularly for infectious disease, oncology, and other diseases. The emerging and legacy pharmaceutical companies are massively investing in the development of these treatment modalities to further expand their pipeline. The successful launch of these candidates after obtaining regulatory approvals from the regulatory authorities is anticipated to increase the competitiveness of the market.Within the research report, the market is segmented on the basis of applications, mRNA type, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.Competitive LandscapeThe exponential rise in the number of COVID-19 cases followed by the growing emphasis of the government for establishing robust vaccination strategies has created a buzz among the pharmaceutical companies to further invest in the development of mRNA-based vaccines for COVID-19. Additionally, due to the growing prominence of mRNA vaccines, pharmaceutical companies are also significantly investing to expand their respective pipeline for non-COVID-19 applications such as infectious diseases, oncology, and other diseases. Due to the presence of a diverse portfolio and intense market penetration, BioNTech SE has been a pioneer in the mRNA vaccines and therapeutics ecosystem.On the basis of region, North America holds the largest share of the mRNA vaccines and therapeutics market for COVID-19 vaccines due to significantly growing fund infusions for mRNA vaccine development, high rise in the pipeline products, presence of established and emerging pharmaceutical companies, presence of ultracold manufacturing and supply chains, and increasing awareness about mRNA-based COVID-19 vaccines, among others. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest rate due to the exponentially rising cases of COVID-19 in the emerging countries, presence of a high population base in the region, and increasing demand for mRNA-based vaccines, among others.Moreover, North America also holds the largest share of the mRNA vaccines and therapeutics market for non-COVID-19 vaccines due to the growing need to develop transformative therapeutics, increasing fund infusions, a favorable regulatory environment, and massively growing attention to establish precision medicine, among others.
Countries Covered :
North America U.S. CanadaEurope Germany Italy France Spain U.K. Rest-of-EuropeAsia-Pacific China Japan South Korea Australia Rest-of-Asia-PacificLatin America Brazil Mexico Rest-of-Latin-AmericaRest-of-the-World
Keywords :
mRNA Vaccines and Therapeutics, mRNA Vaccines and Therapeutics Market, mRNA Vaccines and Therapeutics Industry, mRNA Vaccines and Therapeutics Report, mRNA Vaccines and Therapeutics Market Forecasts, mRNA Vaccines and Therapeutics Market Trends, mRNA Vaccines and Therapeutics Market Companies, mRNA Vaccines and Therapeutics Market Analysis, mRNA Vaccines and Therapeutics Industry Analysis, What is mRNA Vaccines and Therapeutics, mRNA Vaccines and Therapeutics Definition, mRNA Vaccines and Therapeutics Market Competitive Landscape, mRNA Vaccines and Therapeutics Market Drivers, mRNA Vaccines and Therapeutics Market Segments, mRNA Vaccines and Therapeutics Market Outlook, mRNA Vaccines and Therapeutics Market opportunity, mRNA Vaccines and Therapeutics Market Growth, mRNA Vaccines and Therapeutics Market Share, mRNA Vaccines and Therapeutics Market Size, Commercialized Vaccines and Therapeutics Market, mRNA-1273 Vaccines and Therapeutics Market, BNT162b2 mRNA Vaccines and Therapeutics Market, Pipeline Vaccines and Therapeutics Market, CVnCoV mRNA Vaccines and Therapeutics Market, LUNAR-COV19 mRNA Vaccines and Therapeutics Market, MRT5500 mRNA Vaccines and Therapeutics Market, DS-5670 mRNA Vaccines and Therapeutics Market, Oncology mRNA Vaccines and Therapeutics Market, Infectious Diseases mRNA Vaccines and Therapeutics Market, Nucleoside-Modified mRNA Vaccines and Therapeutics Market, Unmodified mRNA Vaccines and Therapeutics Market, Self-Amplifying mRNA Vaccines and Therapeutics Market, North America mRNA Vaccines and Therapeutics Market, Europe mRNA Vaccines and Therapeutics Market, Asia-Pacific mRNA Vaccines and Therapeutics Market, Latin America mRNA Vaccines and Therapeutics Market
Press Release :
The global mRNA vaccines and therapeutics market for COVID-19 vaccines and non-COVID-19 vaccines is projected to reach $28.92 billion and $1.69 billion by 2025 and 2031, respectively, reveals the premium market intelligence study by BIS Research. The study also highlights that the market for mRNA vaccines and therapeutics for COVID-19 vaccines is set to witness a declining CAGR of 13.50% during the period, 2021-2025. (By the end of Q4 2022, the pandemic is expected to transition into an endemic and by Q4 2025, the market is anticipated to drastically decline). Additionally, the study also highlights that the market for mRNA vaccines and therapeutics for non-COVID-19 vaccines is set to witness a CAGR of 95.49% during the period, 2026-2031. (The global mRNA vaccines and therapeutics market (by non-COVID-19 vaccines) has been estimated on the basis of the expected launch of products for non-COVID-19 applications in 2025).The comprehensive study of the global mRNA vaccines and therapeutics market by BIS Research extensively covers the following:• Market numbers on micro-segments that are influencing the market • More than 60 products present in the market, including those which are present in the pipeline• Market share analysis for the commercialized product categories• A detailed global and regional market share analysis, including the scrutiny of more than 14 countries • Study of data of more than 15 companiesBesides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and a visual dashboard of 60+ products. BIS Research study indicates that the growing cases of COVID-19 globally, favorable regulatory environment, and significant external funding for the development of mRNA-based COVID-19 vaccines are fueling the growth of the global mRNA vaccines and therapeutics market. The market intelligence by BIS Research additionally throws a spotlight on the opportunities existing in the market, such as growing emphasis on research and development for non-COVID-19 applications.To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include application, mRNA type, and regions. The biomarker, mRNA type, and regional segments have been further sub-segmented to offer an in-depth analysis of the global mRNA vaccines and therapeutics market.The product and ecosystem analysis of the global market include data analysis on the satisfaction level of different pricing analysis of the commercialized products. With respect to the market segmentation, the application segment has been segregated into COVID-19 mRNA vaccines and non-COVID-19 mRNA vaccines. The COVID-19 mRNA vaccines have been further segmented into commercialized and pipeline vaccines. The non-COVID-19 mRNA vaccines have been segmented into oncology, infectious diseases, and other diseases. The mRNA type segment has been segregated into nucleoside-modified mRNA, unmodified mRNA, and self-amplifying mRNA for both COVID-19 and non-COVID-19 applications.Emphasizing the dominance of the North America region in the global mRNA vaccines and therapeutics market for COVID-19 vaccines in 2020 and 2025, XX, Analyst at BIS Research, states, " In North America, several emerging and legacy companies are focusing on expanding their respective pipeline portfolio and are actively involved in developing mRNA-based candidates for COVID-19. Moreover, significant external funding for the development of mRNA-based COVID-19 vaccines and the presence of technologically advanced supply chains across the region have massively promoted the adoption of mRNA-based COVID-19 vaccines.”Moreover, with the dominance of the North America region in the global mRNA vaccines and therapeutics market for non-COVID-19 vaccines in 2025 and 2031, Nitish Kumar Singh, Principal Analyst at BIS Research, states, " In North America, the growing need to develop novel vaccines and therapies, particularly for oncology and rare diseases, growing emphasis on the establishment of precision medicine strategies, and increasing fund infusions are some of the factors which are responsible to massively promote the adoption of mRNA-based vaccines and therapeutics for non-COVID-19 applications in the forthcoming years.”Key insights are drawn from in-depth interviews with the key opinion leaders of more than 14 leading companies, market participants, and vendors. The key players profiled in the report include Arcturus Therapeutics Holdings Inc., BioNTech SE, CureVac N.V., Daiichi Sankyo Company, Limited., ethris GmbH, GlaxoSmithKline plc, Gennova Biopharmaceuticals Ltd, Moderna, Inc., Pantherna Therapeutics GmbH, Providence Therapeutics, Silence Therapeutics, Translate Bio, VERSAMEB AG, and Verve Therapeutics, Inc.The study also offers strategic recommendations that can help organizations in tracking various products and trends that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.Who should buy this report?• Manufacturers involved in the development and commercialization of mRNA vaccines and therapeutics• Emerging companies in the field of mRNA vaccines and therapeutics to assess the market situationHow can market intelligence on mRNA vaccines and therapeutics add value to an organization’s decision-making process?• Aid in product development and commercialization • Help in targeting a segment for launching new products • Offer go to market access strategies • Help to gain holistic views pertaining to the regions and understand the market potential of the countries• Aid in analyzing the competitive landscape to gain an understanding of the business strategies incorporated by the companiesInsightful Questions Covered to Enable Companies to take Strategic Decisions • What are the major market drivers, challenges, and opportunities in the global mRNA vaccines and therapeutics market?• What are the key development strategies being implemented by the major players in order to sustain in the competitive market? • What are the key regulatory implications in developed and developing regions for the global mRNA vaccines and therapeutics market?• How is each segment of the market expected to grow during the forecast period, 2021-2031?• Who are the leading players with significant offerings to the global mRNA vaccines and therapeutics market, and what is the expected market dominance for each of these leading players?• What are the adoption trends for mRNA vaccines and therapeutics in established economies and emerging economies across the world? • Which companies are anticipated to be highly disruptive in the future, and why?• What are the current clinical unmet needs that are being faced in the global mRNA vaccines and therapeutics market?• What are the dynamics of various application areas and countries, which are impacting the global mRNA vaccines and therapeutics market?• What are the new market opportunities that are influencing the growth of the global mRNA vaccines and therapeutics market?• How is each segment of the market expected to grow during the forecast period from 2021 to 2031? Following are the segment types: • Application • mRNA Type • Region• What are the unmet needs currently existing in the global mRNA vaccines and therapeutics market?
Companies Mentioned :
Arcturus Therapeutics Holdings Inc.BioNTech SECureVac N.V.Daiichi Sankyo Company, Limited.ethris GmbHGlaxoSmithKline plcGennova Biopharmaceuticals LtdModerna, Inc.Pantherna Therapeutics GmbHProvidence TherapeuticsSilence TherapeuticsTranslate BioVERSAMEB AGVerve Therapeutics, Inc.
Press Release :
The global mRNA vaccines and therapeutics market for COVID-19 vaccines and non-COVID-19 vaccines is projected to reach $28.92 billion and $1.69 billion by 2025 and 2031, respectively, reveals the premium market intelligence study by BIS Research. The study also highlights that the market for mRNA vaccines and therapeutics for COVID-19 vaccines is set to witness a declining CAGR of 13.50% during the period, 2021-2025. (By the end of Q4 2022, the pandemic is expected to transition into an endemic and by Q4 2025, the market is anticipated to drastically decline). Additionally, the study also highlights that the market for mRNA vaccines and therapeutics for non-COVID-19 vaccines is set to witness a CAGR of 95.49% during the period, 2026-2031. (The global mRNA vaccines and therapeutics market (by non-COVID-19 vaccines) has been estimated on the basis of the expected launch of products for non-COVID-19 applications in 2025).The comprehensive study of the global mRNA vaccines and therapeutics market by BIS Research extensively covers the following:• Market numbers on micro-segments that are influencing the market • More than 60 products present in the market, including those which are present in the pipeline• Market share analysis for the commercialized product categories• A detailed global and regional market share analysis, including the scrutiny of more than 14 countries • Study of data of more than 15 companiesBesides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and a visual dashboard of 60+ products. BIS Research study indicates that the growing cases of COVID-19 globally, favorable regulatory environment, and significant external funding for the development of mRNA-based COVID-19 vaccines are fueling the growth of the global mRNA vaccines and therapeutics market. The market intelligence by BIS Research additionally throws a spotlight on the opportunities existing in the market, such as growing emphasis on research and development for non-COVID-19 applications.To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include application, mRNA type, and regions. The biomarker, mRNA type, and regional segments have been further sub-segmented to offer an in-depth analysis of the global mRNA vaccines and therapeutics market.The product and ecosystem analysis of the global market include data analysis on the satisfaction level of different pricing analysis of the commercialized products. With respect to the market segmentation, the application segment has been segregated into COVID-19 mRNA vaccines and non-COVID-19 mRNA vaccines. The COVID-19 mRNA vaccines have been further segmented into commercialized and pipeline vaccines. The non-COVID-19 mRNA vaccines have been segmented into oncology, infectious diseases, and other diseases. The mRNA type segment has been segregated into nucleoside-modified mRNA, unmodified mRNA, and self-amplifying mRNA for both COVID-19 and non-COVID-19 applications.Emphasizing the dominance of the North America region in the global mRNA vaccines and therapeutics market for COVID-19 vaccines in 2020 and 2025, XX, Analyst at BIS Research, states, " In North America, several emerging and legacy companies are focusing on expanding their respective pipeline portfolio and are actively involved in developing mRNA-based candidates for COVID-19. Moreover, significant external funding for the development of mRNA-based COVID-19 vaccines and the presence of technologically advanced supply chains across the region have massively promoted the adoption of mRNA-based COVID-19 vaccines.”Moreover, with the dominance of the North America region in the global mRNA vaccines and therapeutics market for non-COVID-19 vaccines in 2025 and 2031, Nitish Kumar Singh, Principal Analyst at BIS Research, states, " In North America, the growing need to develop novel vaccines and therapies, particularly for oncology and rare diseases, growing emphasis on the establishment of precision medicine strategies, and increasing fund infusions are some of the factors which are responsible to massively promote the adoption of mRNA-based vaccines and therapeutics for non-COVID-19 applications in the forthcoming years.”Key insights are drawn from in-depth interviews with the key opinion leaders of more than 14 leading companies, market participants, and vendors. The key players profiled in the report include Arcturus Therapeutics Holdings Inc., BioNTech SE, CureVac N.V., Daiichi Sankyo Company, Limited., ethris GmbH, GlaxoSmithKline plc, Gennova Biopharmaceuticals Ltd, Moderna, Inc., Pantherna Therapeutics GmbH, Providence Therapeutics, Silence Therapeutics, Translate Bio, VERSAMEB AG, and Verve Therapeutics, Inc.The study also offers strategic recommendations that can help organizations in tracking various products and trends that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.Who should buy this report?• Manufacturers involved in the development and commercialization of mRNA vaccines and therapeutics• Emerging companies in the field of mRNA vaccines and therapeutics to assess the market situationHow can market intelligence on mRNA vaccines and therapeutics add value to an organization’s decision-making process?• Aid in product development and commercialization • Help in targeting a segment for launching new products • Offer go to market access strategies • Help to gain holistic views pertaining to the regions and understand the market potential of the countries• Aid in analyzing the competitive landscape to gain an understanding of the business strategies incorporated by the companiesInsightful Questions Covered to Enable Companies to take Strategic Decisions • What are the major market drivers, challenges, and opportunities in the global mRNA vaccines and therapeutics market?• What are the key development strategies being implemented by the major players in order to sustain in the competitive market? • What are the key regulatory implications in developed and developing regions for the global mRNA vaccines and therapeutics market?• How is each segment of the market expected to grow during the forecast period, 2021-2031?• Who are the leading players with significant offerings to the global mRNA vaccines and therapeutics market, and what is the expected market dominance for each of these leading players?• What are the adoption trends for mRNA vaccines and therapeutics in established economies and emerging economies across the world? • Which companies are anticipated to be highly disruptive in the future, and why?• What are the current clinical unmet needs that are being faced in the global mRNA vaccines and therapeutics market?• What are the dynamics of various application areas and countries, which are impacting the global mRNA vaccines and therapeutics market?• What are the new market opportunities that are influencing the growth of the global mRNA vaccines and therapeutics market?• How is each segment of the market expected to grow during the forecast period from 2021 to 2031? Following are the segment types: • Application • mRNA Type • Region• What are the unmet needs currently existing in the global mRNA vaccines and therapeutics market?
Headline :
Global mRNA Vaccines and Therapeutics Market for COVID-19 Vaccines and Non-COVID-19 Vaccines to Reach $28.92 Billion and $1.69 Billion by 2025 and 2031, Respectively, BIS Research Study
Table of Contents :
Executive Summary 1 Product Definition1.1 Inclusions and Exclusions2 Market Scope2.1 Scope of Work2.2 Key Questions Answered in the Report3 Research Methodology3.1 Global mRNA Vaccines and Therapeutics Market: Research Methodology3.2 Primary Data Sources3.3 Secondary Data Sources3.4 Market Estimation Model3.5 Criteria for Company Profiling4 Market Overview4.1 Market Definition4.2 Current Landscape and Future Potential of mRNA-Based Vaccines4.3 Market Footprint and Growth Potential4.3.1 Global mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, 2020-20254.3.2 Global mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), $Million, 2025-20315 Industry Insights5.1 Overview5.2 Legal Requirements and Frameworks in the U.S.5.2.1 Vaccines5.2.1.1 Pre-Clinical and Clinical Development5.2.1.2 Emergency Use Authorization (Public Health Emergencies)5.2.1.3 Assessment of Manufacturing5.2.1.4 Final Approval5.2.2 Therapeutics5.2.2.1 Clinical Trial Authorization5.2.2.2 Marketing Authorization5.2.2.3 Post-Authorization Regulations5.3 Legal Requirements and Frameworks in Europe5.3.1 Vaccines5.3.2 Therapeutics5.3.2.1 Centralized Procedure5.3.2.2 Decentralized Procedure5.3.2.3 Mutual-Recognition Procedure5.3.2.4 National Procedure5.4 Legal Requirements and Frameworks in Asia-Pacific5.4.1 China5.4.2 Japan6 Market Dynamics6.1 Overview6.2 Impact Analysis6.3 Market Drivers6.3.1 Growing Cases of COVID-19 Globally6.3.2 Favorable Regulatory Environment6.3.3 Significant External Funding for the Development of mRNA-Based COVID-19 Vaccines6.4 Market Restraints6.4.1 Logistical Challenges Associated with mRNA-Based COVID-19 Vaccines6.4.2 High Price Associated with mRNA-Based COVID-19 Vaccines6.5 Opportunities6.5.1 Growing Emphasis on Research and Development for Non-COVID-19 Applications7 Competitive Landscape7.1 Key Strategies and Developments7.1.1 Synergistic Activities7.1.2 Product Approvals and Commercialization7.1.3 Funding7.2 Market Share Analysis (by Company), 2020-20218 Global mRNA Vaccines and Therapeutics Market (by Application)8.1 COVID-19 mRNA Vaccines8.1.1 Overview8.1.2 Commercialized Vaccines8.1.2.1 mRNA-12738.1.2.1.1 Supply Agreements for mRNA-12738.1.2.2 BNT162b28.1.2.2.1 Supply Agreements for BNT162b2 (COMIRNATY)8.1.3 Pipeline Vaccines8.1.3.1 CVnCoV8.1.3.2 LUNAR-COV198.1.3.3 MRT55008.1.3.4 DS-56708.2 Non-COVID-19 mRNA Vaccines8.2.1 Overview8.2.2 Oncology8.2.3 Infectious Diseases8.2.4 Other Diseases9 Global mRNA Vaccines and Therapeutics Market (by mRNA Type)9.1 Overview9.2 COVID-19 (by mRNA Type)9.2.1 Nucleoside-Modified mRNA (modRNA)9.2.2 Unmodified mRNA9.2.3 Self-Amplifying mRNA9.3 Non-COVID-19 (mRNA Type)9.3.1 Nucleoside-Modified mRNA (modRNA)9.3.2 Unmodified mRNA9.3.3 Self-Amplifying mRNA10 Global mRNA Vaccines and Therapeutics Market (by Region)10.1 Overview10.2 North America10.2.1 North America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)10.2.1.1 U.S.10.2.1.2 Canada10.2.2 North America mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)10.3 Europe10.3.1 Europe mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)10.3.1.1 Germany10.3.1.2 France10.3.1.3 U.K.10.3.1.4 Italy10.3.1.5 Spain10.3.1.6 Rest-of-Europe10.3.2 Europe mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)10.4 Asia-Pacific10.4.1 Asia-Pacific mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)10.4.1.1 China10.4.1.2 Japan10.4.1.3 South Korea10.4.1.4 Australia10.4.1.5 Rest-of-Asia-Pacific10.4.2 Asia-Pacific mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)10.5 Latin America10.5.1 Latin America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)10.5.1.1 Brazil10.5.1.2 Mexico10.5.1.3 Rest-of-Latin America10.5.2 Latin America mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)10.6 Rest-of-the-World10.6.1 Rest-of-the-World mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)10.6.2 Rest-of-the-World mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)11 Company Profiles11.1 Overview11.2 Arcturus Therapeutics Holdings Inc.11.2.1 Company Overview11.2.2 Role of Arcturus Therapeutics Holdings Inc. in the Global mRNA Vaccines and Therapeutics Market11.2.3 Financials11.2.4 Key Insights About Financial Health of the Company11.2.5 SWOT Analysis11.3 BioNTech SE11.3.1 Company Overview11.3.2 Role of BioNTech SE in the Global mRNA Vaccines and Therapeutics Market11.3.3 Financials11.3.4 Key Insights About Financial Health of the Company11.3.5 SWOT Analysis11.4 CureVac N.V.11.4.1 Company Overview11.4.2 Role of CureVac N.V. in the Global mRNA Vaccines and Therapeutics Market11.4.3 Financials11.4.4 Key Insights About Financial Health of the Company11.4.5 SWOT Analysis11.5 Daiichi Sankyo Company, Limited.11.5.1 Company Overview11.5.2 Role of Daiichi Sankyo Company, Limited. in the Global mRNA Vaccines and Therapeutics Market11.5.3 Financials11.5.4 Key Insights About Financial Health of the Company11.5.5 SWOT Analysis11.6 ethris GmbH11.6.1 Company Overview11.6.2 Role of ethris GmbH in Global mRNA Vaccines and Therapeutics Market11.6.3 SWOT Analysis11.7 GlaxoSmithKline plc11.7.1 Company Overview11.7.2 Role of GlaxoSmithKline plc in Global mRNA Vaccines and Therapeutics Market11.7.3 Financials11.7.4 Key Insights About Financial Health of the Company11.7.5 SWOT Analysis11.8 Gennova Biopharmaceuticals Ltd11.8.1 Company Overview11.8.2 Role of Gennova Biopharmaceuticals Ltd in Global mRNA Vaccines and Therapeutics Market11.8.3 SWOT Analysis11.9 Moderna, Inc.11.9.1 Company Overview11.9.2 Role of Moderna, Inc. in the Global mRNA Vaccines and Therapeutics Market11.9.3 Financials11.9.4 Key Insights About Financial Health of the Company11.9.5 SWOT Analysis11.1 Pantherna Therapeutics GmbH11.10.1 Company Overview11.10.2 Role of Pantherna Therapeutics GmbH in Global mRNA Vaccines and Therapeutics Market11.10.3 SWOT Analysis11.11 Providence Therapeutics11.11.1 Company Overview11.11.2 Role of Providence Therapeutics in Global mRNA Vaccines and Therapeutics Market11.11.3 SWOT Analysis11.12 Silence Therapeutics11.12.1 Company Overview11.12.2 Role of Silence Therapeutics in the Global mRNA Vaccines and Therapeutics Market11.12.3 Financials11.12.4 Key Insights About Financial Health of the Company11.12.5 SWOT Analysis11.13 Translate Bio11.13.1 Company Overview11.13.2 Role of Translate Bio in the Global mRNA Vaccines and Therapeutics Market11.13.3 Financials11.13.4 Key Insights About Financial Health of the Company11.13.5 SWOT Analysis11.14 VERSAMEB AG11.14.1 Company Overview11.14.2 Role of VERSAMEB AG in the Global mRNA Vaccines and Therapeutics Market11.14.3 SWOT Analysis11.15 Verve Therapeutics, Inc.11.15.1 Company Overview11.15.2 Role of Verve Therapeutics, Inc. in the Global mRNA Vaccines and Therapeutics Market11.15.3 SWOT AnalysisList of Tables Table 6.1: Likert ScaleTable 6.2: Impact Analysis of Market DriversTable 6.3: Impact Analysis of Market RestraintsTable 8.1: mRNA Vaccines and Therapeutics for Oncology (Pipeline)Table 8.2: mRNA Vaccines and Therapeutics for Infectious Diseases (Pipeline)Table 8.3: mRNA Vaccines and Therapeutics for Other Diseases (Pipeline)List of Figures Figure 1: Cumulative COVID-19 Cases (as of April 18, 2021)Figure 2: Impact Analysis of Market Drivers and Market Challenges on Global mRNA Vaccines and Therapeutics MarketFigure 3: Global mRNA Vaccines and Therapeutics Market for COVID-19 Vaccines (Commercialized), Q4 2020 Vs. Q4 2025Figure 4: Global mRNA Vaccines and Therapeutics Market for COVID-19 Vaccines (Pipeline), Q2 2021 Vs. Q4 2025Figure 5: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 Vaccines (Pipeline), 2025 Vs. 2031Figure 6: Global mRNA Vaccines and Therapeutics Market (by mRNA Type)Figure 7: Global mRNA Vaccines and Therapeutics Market for COVID-19 Vaccines (by Region), 2020-2025Figure 8: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 Vaccines (by Region), 2025-2031Figure 2.1: Global mRNA Vaccines and Therapeutics, Market SegmentationFigure 3.1: Global mRNA Vaccines and Therapeutics Market Research MethodologyFigure 3.2: Primary Research MethodologyFigure 3.3: Bottom-Up Approach (Segment-Wise Analysis)Figure 3.4: Top-Down Approach (Segment-Wise Analysis)Figure 4.1: Global Revenue for COVID-19 mRNA Vaccines, 2020-2025Figure 4.2: Global mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), 2025-2031Figure 5.1: Steps for Obtaining Marketing AuthorizationFigure 5.2: Vaccine Development StagesFigure 5.3: Steps for Obtaining EMA Approval for VaccinesFigure 6.1: Cumulative COVID-19 Cases (as of April 18, 2021)Figure 6.2: Logistical Challenge Pertaining to mRNA-Based COVID-19 VaccinesFigure 7.1: Share of Key Developments and Strategies, January 2018-March 2021Figure 7.2: Share of Synergistic Activities (by Company), January 2018-March 2021Figure 7.3: Share of Product Approvals and Commercialization (by Company), January 2018-March 2021Figure 7.4: Share of Funding (by Company), January 2018-March 2021Figure 7.5: Market Share Analysis for Global mRNA Vaccines and Therapeutics Market, 2020 and 2021Figure 8.1: Global Revenue for COVID-19 mRNA Vaccines, $Million, 2020-2025Figure 8.2: Global Revenue for COVID-19 mRNA Vaccines (Commercialized), $Million, Q4 2020-Q4 2025Figure 8.3: Global Revenue for COVID-19 mRNA Vaccines (mRNA-1273), $Million, Q4 2020-Q4 2025Figure 8.4: Global Revenue for COVID-19 mRNA Vaccines (BNT162b2), $Million, Q4 2020-Q4 2025Figure 8.5: Expected Revenue from mRNA-Based COVID-19 Vaccines (Pipeline), $Million, Q4 2020-Q4 2025Figure 8.6: Global Estimated Revenue for CVnCoV, $Million, Q2 2021- Q4 2025Figure 8.7: Global Estimated Revenue for LUNAR-COV19, $Million, Q3 2022-Q4 2025Figure 8.8: Global Estimated Revenue for MRT5500, $Million, Q4 2022-Q4 2025Figure 8.9: Global Estimated Revenue for DS-5670, $Million, Q4 2022-Q4 2025Figure 8.10: Global mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)Figure 8.11: Global mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), 2025-2031Figure 8.12: Global mRNA Vaccines and Therapeutics Market (Oncology), $Million, 2025-2031Figure 8.13: Global mRNA Vaccines and Therapeutics Market (Infectious Diseases), $Million, 2025-2031Figure 8.14: Global mRNA Vaccines and Therapeutics Market (Other Diseases), $Million, 2025-2031Figure 9.1: Global mRNA Vaccines and Therapeutics Market (by mRNA Type)Figure 9.2: Global mRNA Vaccines and Therapeutics Market for COVID-19 (Nucleoside-Modified mRNA), $Million, Q42020-Q42025Figure 9.3: Global mRNA Vaccines and Therapeutics Market for COVID-19 (Unmodified mRNA), $Million, Q2 2021-Q4 2025Figure 9.4: Global mRNA Vaccines and Therapeutics Market for COVID-19 (Self-Amplifying mRNA), $Million, Q3 2022-Q4 2025Figure 9.5: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 (Nucleoside-Modified mRNA), $Million, 2025-2031Figure 9.6: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 (Unmodified mRNA), $Million, 2025-2031Figure 9.7: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 (Self-Amplifying mRNA), $Million, 2029-2031Figure 10.1: Global mRNA Vaccines and Therapeutics Market for COVID-19 Vaccines (by Region), 2020 and 2025Figure 10.2: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 Vaccines (by Region), 2025 and2031Figure 10.3: North America: Market DynamicsFigure 10.4: North America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020 vs. Q4 2025Figure 10.5: North America mRNA Vaccines and Therapeutics Market (COVID-19 Vaccines), (by Country), $Million, Q4 2020 vs. Q4 2025Figure 10.6: U.S. mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025Figure 10.7: Canada mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025Figure 10.8: North America mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), $Million, 2025-2031Figure 10.9: Europe: Market DynamicsFigure 10.10: Europe mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025Figure 10.11: Europe mRNA Vaccines and Therapeutics Market (COVID-19 Vaccines), (by Country), $Million, Q4 2020 vs. Q4 2025Figure 10.12: Germany mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025Figure 10.13: France mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025Figure 10.14: U.K. mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025Figure 10.15: Italy mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025Figure 10.16: Spain mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025Figure 10.17: Rest-of-Europe mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2020-Q4 2025Figure 10.18: Europe mRNA Vaccines and Therapeutics (by Non-COVID-19 Vaccines), $Million, 2025-2031Figure 10.19: Asia-Pacific: Market DynamicsFigure 10.20: Asia-Pacific mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025Figure 10.21: Asia-Pacific mRNA Vaccines and Therapeutics Market (COVID-19 Vaccines), (by Country), $Million, Q1 2021 vs. Q4 2025Figure 10.22: China mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q2 2021-Q4 2025Figure 10.23: Japan mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2021-Q4 2025Figure 10.24: South Korea mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q2 2021-Q4 2025Figure 10.25: Australia mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2021-Q4 2025Figure 10.26: Rest-of-Asia-Pacific mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2021-Q4 2025Figure 10.27: Asia-Pacific mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), $Million, 2026-2031Figure 10.28: Latin America: Market DynamicsFigure 10.29: Latin America mRNA Vaccines and Therapeutics Market (COVID-19 Vaccines), (by Country), $Million, Q1 2021 vs. Q4 2025Figure 10.30: Latin America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025Figure 10.31: Brazil mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2021-Q4 2025Figure 10.32: Mexico mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2021-Q4 2025Figure 10.33: Rest-of-Latin America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2021-Q4 2025Figure 10.34: Latin America mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), $Million, 2026-2031Figure 10.35: Rest-of-the-World mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025Figure 10.36: Rest-of-the-World mRNA Vaccines and Therapeutics (by Non-COVID-19 Vaccines), $Million, 2026-2031Figure 11.1: Total Number of Companies ProfiledFigure 11.2: Arcturus Therapeutics Holdings Inc.: Pipeline PortfolioFigure 11.3: Arcturus Therapeutics Holdings Inc.: Overall Financials, 2018-2020Figure 11.4: Arcturus Therapeutics Holdings Inc.: R&D Expenditure, 2018-2020Figure 11.5: Arcturus Therapeutics Holdings Inc.: SWOT AnalysisFigure 11.6: BioNTech SE: Product PortfolioFigure 11.7: BioNTech SE: Pipeline PortfolioFigure 11.8: BioNTech SE: Overall Financials, 2018-2020Figure 11.9: BioNTech SE: Revenue (by Segment), 2018-2020Figure 11.10: BionNTech SE: R&D Expenditure, 2018-2020Figure 11.11: BioNTech SE: SWOT AnalysisFigure 11.12: CureVac N.V.: Pipeline PortfolioFigure 11.13: CureVac N.V.: Overall Financials, 2018-2019Figure 11.14: CureVac N.V.: Revenue (by Region), 2018-2019Figure 11.15: CureVac N.V.: R&D Expenditure, 2018-2019Figure 11.16: CureVac N.V.: SWOT AnalysisFigure 11.17: Daiichi Sankyo Company, Limited: Pipeline PortfolioFigure 11.18: Daiichi Sankyo Company, Limited: Overall Financials, 2017-2019Figure 11.19: Daiichi Sankyo Company, Limited.: Revenue (by Segment), 2017-2019Figure 11.20: Daiichi Sankyo Company, Limited.: Revenue (by Region), 2017-2019Figure 11.21: Daiichi Sankyo Company, Limited: R&D Expenditure, 2017-2019Figure 11.22: Daiichi Sankyo Company, Limited.: SWOT AnalysisFigure 11.23: ethris GmbH: Pipeline PortfolioFigure 11.24: ethris GmbH: SWOT AnalysisFigure 11.25: GlaxoSmithKline plc: Pipeline PortfolioFigure 11.26: GlaxoSmithKline plc: Overall Financials, 2018-2020Figure 11.27: GlaxoSmithKline plc: Revenue (by Segment), 2018-2020Figure 11.28: GlaxoSmithKline plc: Revenue (by Region), 2018-2020Figure 11.29: GlaxoSmithKline plc: R&D Expenditure, 2018-2020Figure 11.30: GlaxoSmithKline plc: SWOT AnalysisFigure 11.31: Gennova Biopharmaceuticals Ltd: Pipeline PortfolioFigure 11.32: Gennova Biopharmaceuticals Ltd: SWOT AnalysisFigure 11.33: Moderna, Inc.: Product PortfolioFigure 11.34: Moderna, Inc: Pipeline PortfolioFigure 11.35: Moderna, Inc.: Overall Financials, 2018-2020Figure 11.36: Moderna, Inc.: Revenue (by Segment), 2018-2020Figure 11.37: Moderna, Inc.: Revenue (by Region), 2020Figure 11.38: Moderna, Inc.: R&D Expenditure, 2018-2020Figure 11.39: Moderna, Inc.: SWOT AnalysisFigure 11.40: Pantherna Therapeutics GmbH: Pipeline PortfolioFigure 11.41: Pantherna Therapeutics GmbH: SWOT AnalysisFigure 11.42: Providence Therapeutics: Pipeline PortfolioFigure 11.43: Providence Therapeutics: SWOT AnalysisFigure 11.44: Silence Therapeutics: Pipeline PortfolioFigure 11.45: Silence Therapeutics: Overall Financials, 2019-2020Figure 11.46: Silence Therapeutics: Revenue (by Segment), 2019-2020Figure 11.47: Silence Therapeutics: Revenue (by Region), 2019-2020Figure 11.48: Silence Therapeutics: R&D Expenditure, 2019-2020Figure 11.49: Silence Therapeutics: SWOT AnalysisFigure 11.50: Translate Bio: Pipeline PortfolioFigure 11.51: Translate Bio: Overall Financials, 2018-2020Figure 11.52: Translate Bio: R&D Expenditure, 2018-2020Figure 11.53: Translate Bio: SWOT AnalysisFigure 11.54: VERSAMEB AG: Pipeline PortfolioFigure 11.55: VERSAMEB AG: SWOT AnalysisFigure 11.56: Verve Therapeutics, Inc.: Pipeline PortfolioFigure 11.57: Verve Therapeutics, Inc.: SWOT Analysis